zurück

Esketamine (re-assessment: treatment-resistant Major Depressive Disorder in combination with a SSRI or SNRI)

 

Subject:

  • Active Substance: Esketamine
  • Name: Spravato®
  • Therapeutic area: Depressive disorder
  • Pharmaceutical company: Janssen-Cilag GmbH

 

Time table:

  • Start: 15.03.2023
  • Publication of assessment: 15.06.2023
  • End of public hearing: 06.07.2023
  • Final decision by G-BA: beginning of September 2023

 

Comparative therapy:

  • Therapy at the physician’s discretion considering the following options: augmentation with lithium or quetiapine retard (as an add-on to the last antidepressant monotherapy) or combination of two antidepressants or electroconvulsive therapy (ECT).